Press releases

Press releases

01 October 2015  - Paris (France)

Stéphane Bessette is appointed Executive Vice President, Human Resources of Ipsen

01 October 2015  - Paris (France)

Ipsen announces release of an additional batch of Increlex® in the U.S.

29 September 2015  - Paris

Ipsen’s partner Lexicon presents phase III TELESTAR study data at ECC 2015 (Vienna, Austria) showing that telotristat etiprate reduces the average number of daily bowel movements in patients with carcinoid syndrome not adequately controlled by somatostatin analogues.

31 August 2015  - Paris (France)

Ipsen announces publication in The Lancet Neurology of the results of the phase III randomized study (NCT01313299) showing efficacy and safety of Dysport® (abobotulinumtoxinA) in adult patients with upper limb spasticity (ULS)

03 August 2015  - Paris (France)

Ipsen’s partner, Lexicon Pharmaceuticals, announces positive results from TELESTAR phase 3 study showing that telotristat etiprate is effective in the treatment of carcinoid syndrome caused by neuroendocrine tumors not adequately controlled by somatostatin analogs

31 July 2015  - Paris (France)

Ipsen: 2015 half-year results

16 July 2015  - Paris (France)

Ipsen announces FDA approval of Dysport® (abobotulinumtoxinA) for injection in the treatment of upper limb spasticity in adults in the United States

02 July 2015  - Paris (France)

Ipsen provides an update on 2020 strategy and outlook at Investor Day

03 June 2015  - Paris (France)

Ipsen initiates a share buyback program Shares will be cancelled to compensate dilution resulting from its free share plans

02 June 2015  - Paris (France)

Ipsen confirms its eligibility for PEA-PME

Updated on 31 July 2015